Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. reported second quarter 2026 results, highlighting clinical and commercial progress alongside continued losses. For the quarter ended June 30, 2026, total revenue was $406,000, up from $301,000 a year earlier, driven by Symvess product revenue of $0.4 million versus $0.1 million in 2025.
Loss from operations was $27.0 million, with a net loss of $36.8 million compared with a net loss of $37.7 million in the prior-year quarter. For the first six months of 2026, the company recorded a net loss of $54.4 million versus net income of $1.5 million in the first half of 2025.
Humacyte ended June 30, 2026 with $79.9 million in cash and cash equivalents, up from $50.5 million at December 31, 2025, and stockholders’ equity of $31.3 million, up from $3.1 million. The company reported breakthrough Phase 3 results for its acellular tissue engineered vessel in dialysis access, plans a supplemental BLA filing in the second half of 2026, and is preparing a Phase 2a CABG study under an accepted IND.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price closed below the $1.00 per share minimum for 30 consecutive business days ended July 30, 2026, violating Nasdaq Listing Rule 5450(a)(1).
Under Nasdaq Listing Rule 5810(c)(3)(A), Humacyte has 180 calendar days, until January 27, 2027, to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days. The notice has no immediate effect on the Nasdaq Global Select Market listing, trading symbol HUMA, or on business operations, while the company monitors its stock price and evaluates options.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Humacyte Inc. common stock. BlackRock reports beneficial ownership of 4,092,430 shares of common stock, representing 1.5% of the outstanding class.
BlackRock has sole voting power and sole dispositive power over all 4,092,430 shares and no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no individual person’s interest exceeds 5% of Humacyte’s total outstanding common shares.
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte, Inc. common stock, representing 6.8% of the outstanding class, all held with shared voting and dispositive power.
As part of FME AG’s FME Reignite strategy, the companies have decided to reduce their Humacyte stake. On July 10, 2026 FMCH entered into a Rule 10b5-1 trading plan with Citigroup Global Markets Inc. to use reasonable best efforts to sell up to 5,000,000 Humacyte shares between the end of the mandatory 30-day cooling-off period and October 31, 2026, subject to volume and other limits. Completion of these sales would lower their beneficial ownership below 5%, after which further sales would no longer be reportable under Section 13(d). FMCH has also instructed its Humacyte board observer to stop attending meetings and receiving confidential materials.
Humacyte, Inc. Schedule 13G disclosure by Davidson Kempner-affiliated reporting persons stating pooled beneficial ownership of Common Stock totaling 12,787,073 shares (reported as 4.74% of the class). The filing ties percentages to 269,638,156 shares outstanding as reported in the Company's Prospectus filed June 11, 2026.
The statement lists related entities (M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value, Davidson Kempner Capital Management LP) and identifies Anthony A. Yoseloff as responsible for voting and investment decisions. The filing classifies the position as ownership of 5% or less for some reporting persons and provides shared voting and dispositive power figures for each entity.
Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte common stock, equal to 6.8% of the outstanding voting shares. All 18,312,735 shares are issued, outstanding, and directly owned by Fresenius Medical Care Holdings, Inc., with Fresenius Medical Care AG as indirect sole shareholder and deemed beneficial owner.
The stake percentage decreased from 8.4% to 6.8% solely because Humacyte’s total outstanding common shares increased to 269,638,156 as of June 12, 2026; Fresenius has neither acquired nor disposed of Humacyte shares since its initial 2021 filing. The amendment also notes that Mollie Miller became a Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. effective May 1, 2026.
Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of 1.08 per share and expire on June 11, 2036.
According to the vesting terms, 25% of the option becomes exercisable on June 11, 2027. The remaining portion vests in equal monthly installments, with 1/48 of the option becoming exercisable on the 11th of each month through June 11, 2030. Following this grant, she holds 80,000 stock options directly.
Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. The first 25% vests on June 11, 2027, with the remaining portion vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. director Max N. Wallace received a grant of stock options for 80,000 shares of Common Stock. The options carry an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds stock options covering 80,000 underlying shares.
The vesting is time-based: the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments (1/48 of the option) on the 11th of each month through June 11, 2030. This is a compensation-related award, not an open-market purchase or sale.
Humacyte, Inc. reported that President and CEO Laura E. Niklason had an indirect acquisition of stock options through her spouse. The grant covers 80,000 stock options for Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036. According to the vesting schedule, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030.